Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

Lihong Peng; Yong Wang; Fen Liu; Xiaotong Qiu; Xinwei Zhang; Fang Chen; Xiaoyin Qian; Yong Li

doi:10.1007/s00262-020-02585-w

April 29, 2020Cancer Immunology ImmunotherapyOpen Access

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

View Full Paper

Ask AI

Bookmark

Share

Abstract

In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peng et al. (2020) studied this question.

synapsesocial.com/papers/69d7e8725c3030ff03d181fc https://doi.org/10.1007/s00262-020-02585-w

View Full Paper

Ask AI

Bookmark

Share

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

Abstract

Discussion

Cite This Study

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Cancer Immunology Immunotherapy

Keep reading

More related papers

More from Cancer Immunology Immunotherapy